Vision in multiple sclerosis: The story, structure-function correlations, and models for neuroprotection

Journal of Neuro-Ophthalmology

Volumn 31, Issue 4, 2011, Pages 362-373

  Sakai, Reiko E ^a   Feller, Daniel J ^a   Galetta, Kristin M ^a   Galetta, Steven L ^a   Balcer, Laura J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINOCULAR VISION; EVOKED VISUAL RESPONSE; HUMAN; MULTIPLE SCLEROSIS; NERVE FIBER; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; VISION; VISUAL ACUITY; VISUAL DISORDER;

CONTRAST SENSITIVITY; EVOKED POTENTIALS, VISUAL; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; OPTIC NEURITIS; QUALITY OF LIFE; TOMOGRAPHY, OPTICAL COHERENCE; VISION DISORDERS; VISION, OCULAR; VISUAL ACUITY; VISUAL PATHWAYS;

EID: 81755188424     PISSN: 10708022     EISSN: 15365166     Source Type: Journal    
DOI: 10.1097/WNO.0b013e318238937f     Document Type: Review

References (105)

1. Optic Neuritis Study Group. Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial. Ophthalmology. 2008;115:1079-1082.
2. Beck RW, Gal RL, Bhatti MT, Brodsky MC, Buckley EG, Chrousos GA, Corbett J, Eggenberger E, Goodwin JA, Katz B, Kaufman DI, Keltner JL, Kupersmith MJ, Miller NR, Moke PS, Nazarian S, Orengo-Nania S, Savino PJ, Shults WT, Smith CH, Trobe JD, Wall M, Xing D; Optic Neuritis Study Group. Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol. 2004;137:77-83. (Pubitemid 38045190)
3. Cleary PA, Beck RW, Anderson MM Jr., Kenny DJ, Backlund JY, Gilbert PR. Design, methods, and conduct of the Optic Neuritis Treatment Trial. Control Clin Trials. 1993;14:123-142. (Pubitemid 23102301)
4. Trobe JD, Beck RW, Moke PS, Cleary PA. Contrast sensitivity and other vision tests in the optic neuritis treatment trial. Am J Ophthalmol. 1996;121:547-553. (Pubitemid 26135863)
5. Volpe NJ. The optic neuritis treatment trial: a definitive answer and profound impact with unexpected results. Arch Ophthalmol. 2008;126:996-999. (Pubitemid 352008388)
6. Keltner JL, Johnson CA, Cello KE, Dontchev M, Gal RL, Beck RW; Optic Neuritis Study Group. Visual field profile of optic neuritis: a final follow-up report from the optic neuritis treatment trial from baseline through 15 years. Arch Ophthalmol. 2010;128:330-337.
7. Balcer LJ, Baier ML, Cohen JA, Kooijmans MF, Sandrock AW, Nano-Schiavi ML, Pfohl DC, Mills M, Bowen J, Ford C, Heidenreich FR, Jacobs DA, Markowitz CE, Stuart WH, Ying GS, Galetta SL, Maguire MG, Cutter GR. Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite. Neurology. 2003;61:1367-1373. (Pubitemid 37463372)
8. Baier ML, Cutter GR, Rudick RA, Miller D, Cohen JA, Weinstock-Guttman B, Mass M, Balcer LJ. Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis. Neurology. 2005;64:992-995. (Pubitemid 40388449)
9. Balcer LJ, Galetta SL, Calabresi PA, Confavreux C, Giovannoni G, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology. 2007;68:1299-1304. (Pubitemid 46625976)
10. Balcer LJ, Galetta SL, Polman PH, Eggenberger E, Calabresi PA, Zhang A, Scanlon JV, Hyde R. Low-contrast acuity measures visual improvement in a phase 3 trial of natalizumab in relapsing MS. Mult Scler. 2010;16:S183.
11. Graves J, Balcer LJ. Eye disorders in patients with multiple sclerosis: natural history and management. Clin Ophthalmol. 2010;4:1409-1422.
12. Trapp BD, Peterson J, Ransohoff RM, Rudick R, M̈rk S, B̈L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998;338:278-285. (Pubitemid 28065253)
13. Evangelou N, Konz D, Esiri MM, Smith S, Palace J, Matthews PM. Size-selective neuronal changes in the anterior optic pathways suggest a differential susceptibility to injury in multiple sclerosis. Brain. 2001;124:1813-1820. (Pubitemid 32845442)
14. DeLuca GC, Williams K, Evangelou N, Ebers GC, Esiri MM. The contribution of demyelination to axonal loss in multiple sclerosis. Brain. 2006;129:1507-1516. (Pubitemid 43999383)
15. Parisi V, Manni G, Spadaro M, Colacino G, Restuccia R, Marchi S, Bucci MG, Pierelli F. Correlation between morphological and functional retinal impairment in multiple sclerosis patients. Invest Ophthalmol Vis Sci. 1999;40:2520-2527. (Pubitemid 29455479)
16. Fisher E, Lee JC, Nakamura K, Rudick RA. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol. 2008;64:255-265.
17. Pirko I, Lucchinetti CF, Sriram S, Bakshi R. Gray matter involvement in multiple sclerosis. Neurology. 2007;68:634-642. (Pubitemid 46667808)
18. Fisniku LK, Chard DT, Jackson JS, Anderson VM, Altmann DR, Miszkiel KA, Thompson AJ, Miller DH. Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol. 2008;64:247-254.
19. Chard D, Miller D. Grey matter pathology in clinically early multiple sclerosis: evidence from magnetic resonance imaging. J Neurol Sci. 2009;282:5-11.
20. Costello F, Coupland S, Hodge W, Lorello GR, Koroluk J, Pan YI, Freedman MS, Zackon DH, Kardon RH. Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol. 2006;59:963-969. (Pubitemid 43830928)
21. Trip SA, Schlottmann PG, Jones SJ, Altmann DR, Garway-Heath DF, Thompson AJ, Plant GT, Miller DH. Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol. 2005;58:383-391. (Pubitemid 41266624)
22. Fisher JB, Jacobs DA, Markowitz CE, Galetta SL, Volpe NJ, Nano-Schiavi ML, Baier ML, Frohman EM, Winslow H, Frohman TC, Calabresi PA, Maguire MG, Cutter GR, Balcer LJ. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology. 2006;113:324-332. (Pubitemid 43170783)
23. Frohman E, Costello F, Zivadinov R, Stuve O, Conger A, Winslow H, Trip A, Frohman T, Balcer L. Optical coherence tomography in multiple sclerosis. Lancet Neurol. 2006;5:853-863. (Pubitemid 44715820)
24. Frohman EM, Fujimoto JG, Frohman TC, Calabresi PA, Cutter G, Balcer LJ. Optical coherence tomography: a window into the mechanisms of multiple sclerosis. Nat Clin Pract Neurol. 2008;4:664-665.
25. Galetta KM, Calabresi PA, Frohman EM, Balcer LJ. Optical coherence tomography (OCT): imaging the visual pathway as a model for neurodegeneration. Neurotherapeutics. 2011;8:117-132.
26. Petzold A, de Boer JF, Schippling S, Vermersch P, Kardon R, Green A, Calabresi PA, Polman C. Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol. 2010;9:921-932.
27. Barkhof F, Calabresi PA, Miller DH, Reingold SC. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol. 2009;5:256-266.
28. Jindahra P, Hedges TR, Mendoza-Santiesteban CE, Plant GT. Optical coherence tomography of the retina: applications in neurology. Curr Opin Neurol. 2010;23:16-23.
29. Lameril C, Newman N, Biousse V. The use of optical coherence tomography in neurology. Rev Neurol Dis. 2009;6: E105-E120.
30. Sakata LM, Deleon-Ortega J, Sakata V, Girkin CA. Optical coherence tomography of the retina and optic nerve - a review. Clin Exp Ophthalmol. 2009;37:90-99.
31. Glisson CC, Galetta SL. Nonconventional optic nerve imaging in multiple sclerosis. Neuroimag Clin N Am. 2009;19:71-79.
32. Kallenbach K, Frederiksen J. Optical coherence tomography in optic neuritis and multiple sclerosis: a review. Eur J Neurol. 2007;14:841-849. (Pubitemid 47106757)
33. Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, Miller A, Petkau J, Rao S, Reingold S, Syndulko K, Thompson A, Wallenberg J, Weinshenker B, Willoughby E. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol. 1997;42:379-382. (Pubitemid 127744543)
34. Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, Miller A, Petkau J, Rao S, Reingold S, Syndulko K, Thompson A, Wallenberg J, Weinshenker B, Willoughby E. Clinical outcomes assessment in multiple sclerosis. Ann Neurol. 1996;40:469-479. (Pubitemid 26304809)
35. Miller DM, Rudick RA, Cutter G, Baier M, Fischer JS. Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life. Arch Neurol. 2000;57:1319-1324.
36. Rudick RA, Cutter G, Reingold S. The multiple sclerosis functional composite: a new clinical outcome measure for multiple sclerosis trials. Mult Scler. 2002;8:359-365.
37. Ozakbas S, Ormeci B, Akdede BB, Alptekin K, Idiman E. Utilization of the auditory consonant trigram test to screen for cognitive impairment in patients with multiple sclerosis: comparison with the paced auditory serial addition test. Mult Scler. 2004;10:686-689. (Pubitemid 39585249)
38. Rudick RA, Polman CH, Cohen JA, Walton MK, Miller AE, Confavreux C, Lublin FD, Hutchinson M, O'Connor PW, Schwid SR, Balcer LJ, Lynn F, Panzara MA, Sandrock AW. Assessing disability progression with the Multiple Sclerosis Functional Composite. Mult Scler. 2009;15:984-997.
39. Ashworth B, Aspinall PA, Mitchell JD. Visual function in multiple sclerosis. Doc Ophthalmol. 1989;73:209-224. (Pubitemid 20230595)
40. Bodis-Wollner I, Brannan JR. Hidden visual loss in optic neuropathy is revealed using Gabor patch contrast perimetry. Clin Neurosci. 1997;4:284-291. (Pubitemid 27382884)
41. Regan D, Raymond J, Ginsburg AP, Murray TJ. Contrast sensitivity, visual acuity and the discrimination of Snellen letters in multiple sclerosis. Brain. 1981;104:333-350. (Pubitemid 12183325)
42. Wender M. Value of Pelli-Robson contrast sensitivity chart for evaluation of visual system in multiple sclerosis patients. Neurol Neurochir Pol. 2007;41:141-143. (Pubitemid 46745851)
43. Kupersmith MJ, Seiple WH, Nelson JI, Carr RE. Contrast sensitivity loss in multiple sclerosis. Selectivity by eye, orientation, and spatial frequency measured with the evoked potential. Invest Ophthalmol Vis Sci. 1984;25:632-639. (Pubitemid 14082972)
44. Leat SJ, Legge GE, Bullimore MA. What is low vision? A re-evaluation of definitions. Optom Vis Sci. 1999;76:198-211. (Pubitemid 29222393)
45. Balcer LJ, Baier ML, Pelak VS, Fox RJ, Shuwairi S, Galetta SL, Cutter GR, Maguire MG. New low-contrast vision charts: reliability and test characteristics in patients with multiple sclerosis. Mult Scler. 2000;6:163-171. (Pubitemid 30392113)
46. Balcer LJ, Frohman EM. Evaluating loss of visual function in multiple sclerosis as measured by low-contrast letter acuity. Neurology. 2010;74(suppl 3):S16-S23.
47. Talman LS, Bisker ER, Sackel DJ, Long DA Jr., Galetta KM, Ratchford JN, Lile DJ, Farrell SK, Loguidice MJ, Remington G, Conger A, Frohman TC, Jacobs DA, Markowitz CE, Cutter GR, Ying GS, Dai Y, Maguire MG, Galetta SL, Frohman EM, Calabresi PA, Balcer LJ. Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann Neurol. 2010;67:749-760.
48. Rosser DA, Cousens SN, Murdoch IE, Fitzke FW, Laidlaw DA. How sensitive to clinical change are ETDRS and logMAR visual acuity measurements? Invest Ophthalmol Vis Sci. 2003;44:3278-3281. (Pubitemid 36909759)
49. Ma SL, Shea JA, Galetta SL, Jacobs DA, Markowitz CE, Maguire MG, Balcer LJ. Self-reported visual dysfunction in multiple sclerosis: new data from the VFQ-25 and development of an MS-specific vision questionnaire. Am J Ophthalmol. 2002;133:686-692. (Pubitemid 34462018)
50. Raphael BA, Galetta KM, Jacobs DA, Markowitz CE, Liu GT, Nano-Schiavi ML, Galetta SL, Maguire MG, Mangione CM, Globe DR, Balcer LJ. Validation and test characteristics of a 10-item neuro-ophthalmic supplement to the NEI-VFQ-25. Am J Ophthalmol. 2006;142:1026-1035.
51. Mowry EM, Loguidice MJ, Daniels AB, Jacobs DA, Markowitz CE, Galetta SL, Nano-Schiavi ML, Cutter GR, Maguire MG, Balcer LJ. Vision related quality of life in multiple sclerosis: correlation with new measures of low and high contrast letter acuity. J Neurol Neurosurg Psychiatry. 2009;80:767-772.
52. Submacular Surgery Trials Research Group. Evaluation of minimum clinically meaningful changes in scores on the National Eye Institute Visual Function Questionnaire (NEI-VFQ) SST Report Number 19. Ophthalmic Epidemiol. 2007;14:205-215.
53. Submacular Surgery Trials Research Group. Responsiveness of the National Eye Institute Visual Function Questionnaire to changes in visual acuity: findings in patients with subfoveal choroidal neovascularization-SST Report Number 1. Arch Ophthalmol. 2003;121:531-539.
54. McKean-Cowdin R, Varma R, Wu J, Hays RD, Azen SP; Los Angeles Latino Eye Study Group. Severity of visual field loss and health-related quality of life. Am J Ophthalmol. 2007;143:1013-1023. (Pubitemid 46764652)
55. Globe DR, Wu J, Azen SP, Varma R; Los Angeles Latino Eye Study Group. The impact of visual impairment on self-reported visual functioning in Latinos: The Los Angeles Latino Eye Study. Ophthalmology. 2004;111:1141-1149. (Pubitemid 38736993)
56. Pineles SL, Birch EE, Talman LS, Sackel DJ, Frohman EM, Calabresi PA, Galetta SL, Maguire MG, Balcer LJ. One eye or two: a comparison of binocular and monocular low-contrast acuity testing in multiple sclerosis. Am J Ophthalmol. 2011;152:133-140.
57. Newman NJ, Wolfe JM, Stewart MI, Lessell S. Binocular visual function in patients with a history of monocular optic neuritis. Clin Vis Sci. 1991;6:95-107.
58. Wu GF, Schwartz ED, Lei T, Souza A, Mishra S, Jacobs DA, Markowitz CE, Galetta SL, Nano-Schiavi ML, Desiderio LM, Cutter GR, Calabresi PA, Udupa JK, Balcer LJ. Relation of vision to global and regional brain MRI in multiple sclerosis. Neurology. 2007;69:2128-2135. (Pubitemid 350294693)
59. Kolappan M, Henderson AP, Jenkins TM, Wheeler-Kingshott CA, Plant GT, Thompson AJ, Miller DH. Assessing structure and function of the afferent visual pathway in multiple sclerosis and associated optic neuritis. J Neurol. 2009;256:305-319.
60. Halliday AM, McDonald WI, Mushin J. Visual evoked response in diagnosis of multiple sclerosis. BMJ. 1973;4:661-664.
61. Thurtell MJ, Bala E, Yaniglos SS, Rucker JC, Peachey NS, Leigh RJ. Evaluation of optic neuropathy in multiple sclerosis using low-contrast visual evoked potentials. Neurology. 2009;73:1849-1857.
62. Laron M, Cheng H, Zhang B, Schiffman JS, Tang RA, Frishman LJ. Assessing visual pathway function in multiple sclerosis patients with multifocal visual evoked potentials. Mult Scler. 2009;15:1431-1441.
63. Naismith RT, Tutlam NT, Xu J, Shepherd JB, Klawiter EC, Song SK, Cross AH. Optical coherence tomography is less sensitive than visual evoked potentials in optic neuritis. Neurology. 2009;73:46-52.
64. Sepulcre J, Gõi J, Masdeu JC, Bejarano B, Vélez de Mendizábal N, Toledo JB, Villoslada P. Contribution of white matter lesions to gray matter atrophy in multiple sclerosis: evidence from voxel-based analysis of T1 lesions in the visual pathway. Arch Neurol. 2009;66:173-179.
65. Ikuta F, Zimmerman HM. Distribution of plaques in seventy autopsy cases of multiple sclerosis in the United States. Neurology. 1976;26:26-28.
66. Toussaint D, Périer O, Verstappen A, Bervoets S. Clinicopathological study of the visual pathways, eyes, and cerebral hemispheres in 32 cases of disseminated sclerosis. J Clin Neuro-Ophthalmol. 1983;3:211-220. (Pubitemid 14229303)
67. Sisto D, Trojano M, Vetrugno M, Trabucco T, Iliceto G, Sborgia C. Subclinical visual involvement in multiple sclerosis: a study by MRI, VEPs, frequency-doubling perimetry, standard perimetry, and contrast sensitivity. Invest Ophthalmol Vis Sci. 2005;46:1264-1268. (Pubitemid 41685862)
68. Lycke J, Tollesson PO, Frisén L. Asymptomatic visual loss in multiple sclerosis. J Neurol. 2001;248:1079-1086. (Pubitemid 34134545)
69. Engell T, Trojaborg W, Raun NE. Subclinical optic neuropathy in multiple sclerosis. A neuro-ophthalmological investigation by means of visually evoked response, Farnworth-Munsell 100 Hue test and Ishihara test and their diagnostic value. Acta Ophthalmol (Copenh). 1987;65:735-740. (Pubitemid 18022797)
70. Cheng H, Laron M, Schiffman JS, Tang RA, Frishman LJ. The relationship between visual field and retinal nerve fiber layer measurements in patients with multiple sclerosis. Invest Ophthalmol Vis Sci. 2007;48:5798-5805. (Pubitemid 351260886)
71. Pulicken M, Gordon-Lipkin E, Balcer LJ, Frohman E, Cutter G, Calabresi PA. Optical coherence tomography and disease subtype in multiple sclerosis. Neurology. 2007;69:2085-2092. (Pubitemid 350175711)
72. Costello F, Hodge W, Pan YI, Freedman M, DeMeulemeester C. Differences in retinal nerve fiber layer atrophy between multiple sclerosis subtypes. J Neurol Sci. 2009;281:74-79.
73. Henderson AP, Trip SA, Schlottmann PG, Altmann DR, Garway-Heath DF, Plant GT, Miller DH. An investigation of the retinal nerve fibre layer in progressive multiple sclerosis using optical coherence tomography. Brain. 2008;131:277-287.
74. Gordon-Lipkin E, Chodkowski B, Reich DS, Smith SA, Pulicken M, Balcer LJ, Frohman EM, Cutter G, Calabresi PA. Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology. 2007;69:1603-1609. (Pubitemid 350287144)
75. Sepulcre J, Murie-Fernandez M, Salinas-Alaman A, García-Layana A, Bejarano B, Villoslada P. Diagnostic accuracy of retinal abnormalities in predicting disease activity in MS. Neurology. 2007;68:1488-1494. (Pubitemid 46685919)
76. Cettomai D, Pulicken M, Gordon-Lipkin E, Salter A, Frohman TC, Conger A, Zhang X, Cutter G, Balcer LJ, Frohman EM, Calabresi PA. Reproducibility of optical coherence tomography in multiple sclerosis. Arch Neurol. 2008;65:1218-1222.
77. Zaveri MS, Conger A, Salter A, Frohman TC, Galetta SL, Markowitz CE, Jacobs DA, Cutter GR, Ying GS, Maguire MG, Calabresi PA, Balcer LJ, Frohman EM. Retinal imaging by laser polarimetry and optical coherence tomography evidence of axonal degeneration in multiple sclerosis. Arch Neurol. 2008;65:924-928. (Pubitemid 352008476)
78. Salter AR, Conger A, Frohman TC, Zivadinov R, Eggenberger E, Calabresi P, Cutter G, Balcer L, Frohman EM. Retinal architecture predicts pupillary reflex metrics in MS. Mult Scler. 2008;15:479-486.
79. Pueyo V, Ara JR, Almarcegui C, Martin J, Güerri N, García E, Pablo LE, Honrubia FM, Fernandez FJ. Sub-clinical atrophy of the retinal nerve fibre layer in multiple sclerosis. Acta Ophthalmol. 2010;88:748-752.
80. Costello F, Hodge W, Pan YI, Metz L, Kardon RH. Retinal nerve fiber layer and future risk of multiple sclerosis. Can J Neurol Sci. 2008;35:482-487.
81. Burkholder BM, Osborne B, Loguidice MJ, Bisker E, Frohman TC, Conger A, Ratchford JN, Warner C, Markowitz CE, Jacobs DA, Galetta SL, Cutter GR, Maguire MG, Calabresi PA, Balcer LJ, Frohman EM. Macular volume determined by optical coherence tomography as a measure of neuronal loss in multiple sclerosis. Arch Neurol. 2009;66:1366-1372.
82. Syc SB, Warner CV, Hiremath GS, Farrell SK, Ratchford JN, Conger A, Frohman T, Cutter G, Balcer LJ, Frohman EM, Calabresi PA. Reproducibility of high-resolution optical coherence tomography in multiple sclerosis. Mult Scler. 2010;16:829-839.
83. Kanamori A, Escano MF, Eno A, Nakamura M, Maeda H, Seya R, Ishibashi K, Negi A. Evaluation of the effect of aging on retinal nerve fiber layer thickness measured by optical coherence tomography. Ophthalmologica. 2003;217:273-278. (Pubitemid 36693890)
84. Henderson APD, Altmann DR, Trip AS, Kallis C, Jones SJ, Schlottmann PG, Garway-Heath DF, Plant GT, Miller DH. A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials. Brain. 2010;133:2592-2602.
85. Costello F, Hodge W, Pan YI, Eggenberger E, Freedman MS. Using retinal architecture to help characterize multiple sclerosis patients. Can J Ophthalmol. 2010;45:520-526.
86. Bock M, Brandt AU, Kuchenbecker J, D̈rr J, Pfueller CF, Weinges-Evers N, Gaede G, Zimmermann H, Bellmann-Strobl J, Ohlraun S, Zipp F, Paul F. Impairment of contrast visual acuity as a functional correlate of retinal nerve fibre layer thinning and total macular volume reduction in multiple sclerosis. Br J Ophthalmol. [published online ahead of print March 3, 2011] doi:10.1136/bjo.2010.193581.
87. Merle H, Olindo S, Donnio A, Beral L, Richer R, Smadja D, Cabre P. Retinal nerve fiber layer thickness and spatial and temporal contrast sensitivity in multiple sclerosis. Eur J Ophthalmol. 2010;20:158-166.
88. Galetta KM, Graves J, Talman LS, Lile DJ, Frohman EM, Calabresi PA, Galetta SL, Balcer LJ. Visual pathway loss in benign multiple sclerosis: a longitudinal study. J Neuroophthalmol. 2011; In press.
89. Shiee N, Bazin PL, Ozturk A, Reich DS, Calabresi PA, Pham DL. A topology-preserving approach to the segmentation of brain images with multiple sclerosis lesions. NeuroImage. 2010;49:1524-1535.
90. Filippi M, Rocca MA, Calabrese M, Sormani MP, Rinaldi F, Perini P, Comi G, Gallo P. Intracortical lesions: relevance for new MRI diagnostic criteria for multiple sclerosis. Neurology. 2010;75:1988-1994.
91. Pitt D, Boster A, Pei W, Wohleb E, Jasne A, Zachariah CR, Rammohan K, Knopp MV, Schmalbrock P. Imaging cortical lesions in multiple sclerosis with ultra-high-field magnetic resonance imaging. Arch Neurol. 2010;67:812-818.
92. Watson GM, Keltner JL, Chin EK, Harvey D, Nguyen A, Park SS. Comparison of retinal nerve fiber layer and central macular thickness measurements among five different optical coherence tomography instruments in patients with multiple sclerosis and optic neuritis. J Neuroophthalmol. 2011;31:110-116.
93. Garcia-Martin E, Pinilla I, Idoipe M, Fuertes I, Pueyo V. Intra and inter-operator reproducibility of retinal nerve fiber and macular thickness measurements using Cirrus Fourierdomain OCT. Acta Ophthalmol. 2011;89:e23-e29.
94. Sull AC, Vuong LN, Price LL, Srinivasan VJ, Gorczynska I, Fujimoto JG, Schuman JS, Duker JS. Comparison of spectral domain optical coherence tomography instruments for assessment of normal macular thickness. Retina. 2010;30:235-245.
95. Wollstein G, Kagemann L, Bilonick RA, Ishikawa H, Folio LS, Gabriele ML, Ungar AK, Duker JS, Fujimoto JG, Schuman JS. Retinal nerve fibre layer and visual function loss in glaucoma: the tipping point. Br J Ophthalmol. [published online ahead of print April 8, 2011] doi:10.1136/bjo.2010.196907.
96. Saidha S, Syc SB, Ibrahim MA, Eckstein C, Warner CV, Farrell SK, Oakley JD, Durbin MK, Meyer SA, Balcer LJ, Frohman EM, Rosenzweig JM, Newsome SD, Ratchford JN, Nguyen QD, Calabresi PA. Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain. 2011;134:518-533.
97. Davies EC, Galetta KM, Sackel DJ, Talman LS, Frohman EM, Calabresi PA, Galetta SL, Balcer LJ. Retinal ganglion cell layer volumetric assessment by spectral-domain optical coherence tomography in multiple sclerosis: application of a highprecision manual estimation technique. J Neuroophthalmol. 2011;31:260-264.
98. Tan O, Li G, Lu AT, Varma R, Huang D; Advanced Imaging for Glaucoma Study Group. Mapping of macular substructures with optical coherence tomography for glaucoma diagnosis. Ophthalmology. 2008;115:949-956. (Pubitemid 351749686)
99. Tan O, Chopra V, Lu AT, Schuman JS, Ishikawa H, Wollstein G, Varma R, Huang D. Detection of macular ganglion cell loss in glaucoma by Fourier-domain optical coherence tomography. Ophthalmology. 2009;116:2305-2314.
100. Ishikawa H, Stein DM, Wollstein G, Beaton S, Fujimoto JG, Schuman JS. Macular segmentation with optical coherence tomography. Invest Ophthalmol Vis Sci. 2005;46:2012-2017.
101. Green A, McQuaid S, Hauser SL, Allen IV, Lyness R. Ocular pathology in multiple sclerosis: retinal atrophy and inflammation irrespective of disease duration. Brain. 2010;133:1591-1601.
102. Shindler KS, Ventura E, Dutt M, Elliott P, Fitzgerald DC, Rostami A. Oral resveratrol reduces neuronal damage in a model of multiple sclerosis. J Neuroophthalmol. 2010;30:328-339.
103. Walter SD, Ishikawa H, Galetta KM, Sakai RE, Feller DJ, Wilson JA, Maguire MG, Galetta SL, Frohman E, Calabresi PA, Schuman JS, Balcer LJ. Ganglion cell loss in relation to visual disability in multiple sclerosis. Mult Scler. Nov 2011 Suppl. Abstract. In press.
104. Keltner JL, Cello KE, Balcer LJ, Calabresi PA, Markowitz CE, Werner JS. Stratus OCT quality control in two multi-centre multiple sclerosis clinical trials. J Neuroophthalmol. 2011;35:57-64.
105. Werner JS, Keltner JL, Zawadzki RJ, Choi SS. Outer retinal abnormalities associated with inner retinal pathology in nonglaucomatous and glaucomatous optic neuropathies. Eye. 2011;25:279-289.